Vorapaxar

Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM) . Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP) -induced platelet aggregation in a dose-dependent manner[1].

Product Specifications

CAS Number

[618385-01-6]

Product Name Alternative

SCH 530348

UNSPSC

12352005

Hazard Statement

H371, H373, H400, H410

Target

Protease Activated Receptor (PAR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Vorapaxar.html

Purity

99.85

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(O[C@@H]1C)[C@@]2([H])[C@]1([H])[C@@H](/C=C/C3=NC=C(C=C3)C4=CC=CC(F)=C4)[C@]([C@](C5)([H])C2)([H])CC[C@H]5NC(OCC)=O

Molecular Formula

C29H33FN2O4

Molecular Weight

492.58

Precautions

H371, H373, H400, H410

References & Citations

[1]Khoufache K, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan;123 (1) :206-14.|[2]Kehinde O, et al. Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci. 2016 Apr-Jun;8 (2) :98-105.